Premium
Review article: pH, healing and symptom relief with rabeprazole treatment in acid‐related disorders
Author(s) -
Robinson M.
Publication year - 2004
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/j.1365-2036.2004.02163.x
Subject(s) - rabeprazole , esomeprazole , lansoprazole , omeprazole , medicine , pantoprazole , proton pump inhibitor , gastric acid , gastroenterology , gerd , aspirin , pharmacology , reflux , disease , stomach
Summary Control of gastric acid secretion by antisecretory agents has been the cornerstone of therapy in the successful management of all acid‐related disorders, including gastro‐oesophageal reflux disease (GERD), and duodenal and gastric ulcer. Treatment efficacy has been strongly correlated with degree and duration of acid suppression within the 24‐h period and with total duration of therapy. All proton pump inhibitors are highly effective for the healing of ulcers and erosive oesophagitis. All have closely similar mechanisms of action, yet important pharmacological differences exist, which can significantly impact certain aspects of their clinical efficacy. Rabeprazole's rapid activation over a wide pH range may be the explanation for its early onset of effective acid inhibition compared with other proton pump inhibitors such as omeprazole, lansoprazole and pantoprazole. Like rabeprazole, esomeprazole is also a potent inhibitor of gastric acid at steady state, although it is thought that rabeprazole may provide enhanced first‐day acid suppression compared with esomeprazole. First‐day antisecretory efficacy should produce faster symptom relief, a hypothesis supported by clinical data. Moreover, drugs with pharmacological profiles that include both rapid onset and potent antisecretory effects should help control healthcare costs by reducing the need for otherwise commonly used twice‐daily proton pump inhibitor administration.